Biophysical properties of the clinical-stage antibody landscape

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 5, 2017, Pages 944-949

  Jain, Tushar ^a   Sun, Tingwan ^a   Durand, Stéphanie ^a   Hall, Amy ^a   Houston, Nga Rewa ^a   Nett, Juergen H ^a   Sharkey, Beth ^a   Bobrowicz, Beata ^a   Caffry, Isabelle ^a   Yu, Yao ^a   Cao, Yuan ^a   Lynaugh, Heather ^a   Brown, Michael ^a   Baruah, Hemanta ^a   Gray, Laura T ^a   Krauland, Eric M ^a   Xu, Yingda ^a   Vásquez, Maximiliano ^a   Wittrup, K Dane ^a  

^a Adimab LLC   (United States)

Author keywords

Biophysical properties; Developability; Manufacturability; Monoclonal antibody; Nonspecificity

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G;

AMINO ACID SEQUENCE; ARTICLE; BIOPHYSICS; CLUSTER ANALYSIS; DRUG MANUFACTURE; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; PRIORITY JOURNAL; SIZE EXCLUSION CHROMATOGRAPHY; CHEMISTRY; DRUG APPROVAL; DRUG DEVELOPMENT; HEK293 CELL LINE; HUMAN; PROCEDURES;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; BIOPHYSICAL PHENOMENA; DRUG APPROVAL; DRUG DISCOVERY; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G;

EID: 85011003450     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1616408114     Document Type: Article

References (33)

1. Jacobs SA, Wu SJ, Feng Y, Bethea D, O'Neil KT (2010) Cross-interaction chromatography: A rapid method to identify highly soluble monoclonal antibody candidates. Pharm Res 27(1):65-71.
2. Nishi H, et al. (2011) Fc domain mediated self-association of an IgG1 monoclonal antibody under a low ionic strength condition. J Biosci Bioeng 112(4):326-332.
3. Sule SV, et al. (2011) High-throughput analysis of concentration-dependent antibody self-association. Biophys J 101(7):1749-1757.
4. Hötzel I, et al. (2012) A strategy for risk mitigation of antibodies with fast clearance. MAbs 4(6):753-760.
5. Lauer TM, et al. (2012) Developability index: A rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci 101(1):102-115.
6. Sule SV, Dickinson CD, Lu J, Chow CK, Tessier PM (2013) Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates. Mol Pharm 10(4):1322-1331.
7. Sun T, et al. (2013) High throughput detection of antibody self-interaction by biolayer interferometry. MAbs 5(6):838-841.
8. Xu Y, et al. (2013) Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: A FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel 26(10):663-670.
9. Geng SB, Cheung JK, Narasimhan C, Shameem M, Tessier PM (2014) Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactions. J Pharm Sci 103(11):3356-3363.
10. Jayaraman J, et al. (2014) Plasmonic measurements of monoclonal antibody self-association using self-interaction nanoparticle spectroscopy. Biotechnol Bioeng 111(8):1513-1520.
11. Liu Y, et al. (2014) High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. MAbs 6(2):483-492.
12. Jarasch A, et al. (2015) Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci 104(6):1885-1898.
13. Kohli N, et al. (2015) A novel screening method to assess developability of antibody-like molecules. MAbs 7(4):752-758.
14. Obrezanova O, et al. (2015) Aggregation risk prediction for antibodies and its application to biotherapeutic development. MAbs 7(2):352-363.
15. Sharma VK, et al. (2014) In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability. Proc Natl Acad Sci USA 111(52):18601-18606.
16. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46(1-3):3-26.
17. Mouquet H, et al. (2010) Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467(7315):591-595.
18. Estep P, et al. (2015) An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies. MAbs 7(3):553-561.
19. Kelly RL, et al. (2015) High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs 7(4):770-777.
20. Kelly RL, et al. (2016) Target-independent variable region mediated effects on antibody clearance can be FcRn independent. MAbs 8(7):1269-1275.
21. Datta-Mannan A, et al. (2015) The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. MAbs 7(6):1084-1093.
22. Sigounas G, Harindranath N, Donadel G, Notkins AL (1994) Half-life of polyreactive antibodies. J Clin Immunol 14(2):134-140.
23. Schoch A, et al. (2015) Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci USA 112(19):5997-6002.
24. Kowalski JM, Parekh RN, Mao J, Wittrup KD (1998) Protein folding stability can determine the efficiency of escape from endoplasmic reticulum quality control. J Biol Chem 273(31):19453-19458.
25. Kowalski JM, Parekh RN, Wittrup KD (1998) Secretion efficiency in Saccharomyces cerevisiae of bovine pancreatic trypsin inhibitor mutants lacking disulfide bonds is correlated with thermodynamic stability. Biochemistry 37(5):1264-1273.
26. Wang F, et al. (2013) Somatic hypermutation maintains antibody thermodynamic stability during affinity maturation. Proc Natl Acad Sci USA 110(11):4261-4266.
27. Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6(11):881-890.
28. Waring MJ, et al. (2015) An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov 14(7):475-486.
29. Spencer S, Bethea D, Raju TS, Giles-Komar J, Feng Y (2012) Solubility evaluation of murine hybridoma antibodies. MAbs 4(3):319-325.
30. Hartmann S, Kocher HP (2016) Best practices in assessment of developability of biopharmaceutical candidates. Developability of Biotherapeutics: Computational Approaches, eds Kumar S, Singh SK (CRC, Boca Raton, FL), pp 155-174.
31. Warne NW (2011) Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development. Eur J Pharm Biopharm 78(2):208-212.
32. He F, Woods CE, Becker GW, Narhi LO, Razinkov VI (2011) High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations. JPharm Sci 100(12):5126-5141.
33. Anderson TW, Darling DA (1952) Asymptotic theory of certain "goodness of fit" criteria based on stochastic processes. Ann Math Stat 23(2):193-212.